On June 10, 2026, Jade Biosciences, Inc. filed Amended and Restated Articles of Incorporation following stockholder approval at the 2026 Annual Meeting to waive jury trials in certain circumstances. Additionally, the Board adopted Amended and Restated Bylaws effective June 9, 2026, which modernize corporate governance by permitting virtual meetings, updating record date rules for postponed meetings, and revising the voting standard for non-director matters to a simple majority of votes cast. The company also elected Class II Directors Christopher Cain and Tom Frohlich and ratified PricewaterhouseCoopers LLP as its independent auditor. Jade Biosciences is a biotechnology company.
